Overview
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
Eligibility
Inclusion Criteria:
- DME, treatment-naïve or previously-treated
- Male or female ≥18 years of age with Type 1 or Type 2 diabetes mellitus and a HbA1c of ≤12%
- Capable of giving informed signed consent
Exclusion Criteria:
- Active iris or angle neovascularization or neovascular glaucoma in the Study Eye.
- Current or history of retinal detachment (tractional or rhegmatogenous) in the Study Eye


